Amendment to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) The compound of formula I or pharmaceutically acceptable esters, ethers, and/or salts thereof:



(I)

wherein:

Q is selected from the group consisting of -O- and -N(R)-;

R is selected from the group consisting of -H and -C_{1-6}alkyl;

Z is selected from the group consisting of -C_{1-6}alkyl-O- and -C_{1-4}alkyl-cycloalkyl-O-; and

Y is selected from the group consisting of tetrazoyl, oxazoyl, thiazoyl, pyridyl, N-oxo-pyridyl, pyrimidinyl, and pyrazinyl; each valence permitting unsubstituted, mono- or polysubstituted with one or more instances selected from the group consisting of halo, -OR, -NR_2, -SR, -C_{1-6}alkyl, -CO_2H, -CO_2Ph, and -CO_2C_{1-6}alkyl.

2. (Original) The compound of claim 1 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein:

Q is –N(R)-;

R is selected from the group consisting of -H and -C_{1-6}alkyl;

Z is selected from the group consisting of -C_{1-6}alkyl-O- and -C_{1-4}alkyl-cycloalkyl-O-; and

Y is selected from the group consisting of tetrazoyl, oxazoyl, thiazoyl, pyridyl, N-oxo-pyridyl, pyrimidinyl, and pyrazinyl; valence permitting unsubstituted, mono- or polysubstituted with one or more instances selected from the group consisting of halo, -OR, -NR_2, -SR, -C_{1-6}alkyl, -CO_2H, -CO_2Ph, and -CO_2C_{1-6}alkyl.

3. (Original) The compound of claim 2 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Z is -C_{1-6}alkyl-O-.

4. (Original) The compound of claim 3 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Z is -*n*-propyl-O-.

5. (Original) The compound of claim 4 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Y is pyridyl.

6. (Original) The compound of claim 1 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein:

Q is O;

R is selected from the group consisting of -H and -C_{1-6}alkyl;

Z is selected from the group consisting of -C_{1-6}alkyl-O- and -C_{1-4}alkyl-cycloalkyl-O-; and

Y is selected from the group consisting of tetrazoyl, oxazoyl, thiazoyl, pyridyl, N-oxo-pyridyl, pyrimidinyl, and pyrazinyl; each valence permitting unsubstituted, mono- or polysubstituted with one or more instances selected from the group consisting of halo, -OR, -NR_2, -SR, -C_{1-6}alkyl, -CO_2H, -CO_2Ph, and -CO_2C_{1-6}alkyl.

7. (Original) The compound of claim 6 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Z is -C_{1-6}alkyl-O-.

8. (Original) The compound of claim 7 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Z is -*n*-propyl-O-.

9. (Original) The compound of claim 8 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Y is pyridyl.

10. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient the compound of formula I



(I)

wherein:

Q is selected from the group consisting of -O- and -N(R)-;

R is selected from the group consisting of -H and -C_{1-6}alkyl;

Z is selected from the group consisting of -C_{1-6}alkyl-O- and -C_{1-4}alkyl-cycloalkyl-O-; and

Y is selected from the group consisting of tetrazoyl, oxazoyl, thiazoyl, pyridyl, N-oxo-pyridyl, pyrimidinyl, and pyrazinyl; each valence permitting unsubstituted, mono- or polysubstituted with one or more instances selected from the group consisting of halo, -OR, -NR_2, -SR, -C_{1-6}alkyl, -CO_2H, -CO_2Ph, and -CO_2C_{1-6}alkyl.

11. (Currently Amended) A method of treatment of ~~a cancer~~ breast cancer or lymphoma in a patient, which method comprises administering to a patient a therapeutically effective amount of the compound of claim 1.

12. (Currently Amended) A method of treatment of ~~a cancer~~ breast cancer or lymphoma in a patient, which method comprises administering to a patient a therapeutically effective amount of the composition of claim 9.

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (New) The method of claim 11, wherein the lymphoma is B-cell lymphoma.

18. (New) The method of claim 12, wherein the lymphoma is B-cell lymphoma.